There is evidence of poor prognosis in women with pregnancy-associated breast cancer (PABC) diagnosed during pregnancy or within 2 years of delivery. Using a large, population-based cohort, we examined clinicopathologic features and survival in women with PABC. A cohort of women diagnosed with invasive breast cancer between 1992 and 2009 at ages 15-44 years was identified in the Swedish Cancer Register and the Breast Cancer Quality Registers. Dates of childbirths for each woman were retrieved from the Swedish Multi-Generation Register. Age-standardized distributions of tumor stage (tumor size, nodal status, metastasis), Elston grade and ER/PR/HER2 status were compared between nulliparous women and women with breast cancer during pregnancy and up to 10 years postdelivery. Adjusted hazard ratios for all-cause mortality rates among patients were estimated using Cox regression. We identified 1,661 nulliparous women with breast cancer, 778 women with PABC (97 during pregnancy, 270 within first and 411 within second year postdelivery) and 3,598 during 2-10 years postdelivery. Compared to nulliparous women, women with PABC, and especially women diagnosed 0-12 months after delivery, had more advanced T and N stage, and higher proportions of ER/PR negative, HER2 positive and triple-negative tumors. Increased hazard ratios were observed in women diagnosed within 5 years of delivery after adjustment for age, year, education and region. Following additional adjustment for tumor characteristics, the hazard ratios were attenuated and nonsignificant. The poorer prognosis observed in women with PABC appears to be largely explained by more adverse tumor characteristics at diagnosis.
Introduction
Pregnancy-associated breast cancer (PABC) is commonly defined as a breast cancer diagnosed during pregnancy and within 1 or 2 years of delivery. 1 Because of a continued trend of delayed childbearing, the number of women with PABC is expected to increase. [1] [2] [3] [4] There is evidence suggesting that tumors diagnosed during pregnancy and around delivery exhibit adverse prognostic characteristics, including larger size, regional spread and negative estrogen (ER) and progesterone receptor (PR) status. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Several studies have also observed a poorer survival among women with PABC. [22] [23] [24] [25] In some, 3, 7, 13, 14, 17, 18, [25] [26] [27] [28] but not all studies, 6, 10, 11, 16, 22 the poorer outcome remained following adjustment for stage at diagnosis.
Since the effects of childbearing on breast cancer biology and outcome may extend beyond the PABC window, it is also of interest to examine tumor features and survival in women diagnosed up to 5 or 10 years postdelivery. 18, 19, 22, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Tumors detected more than 2 years postdelivery are less likely to be affected by detection problems associated with pregnancy and lactation, and may exhibit different clinicopathologic characteristics. 29 We aimed to compare tumor characteristics in women with PABC to nulliparous women with breast cancer and women diagnosed 2-10 years postdelivery. We also assessed whether differences in tumor characteristics can explain the previously observed poorer prognosis in women with PABC.
Materials and Methods

Study design and patients
Using the nationwide Swedish Cancer Register (SCR), we identified a population-based cohort of women aged 15-44 years diagnosed with invasive breast cancer between 1992 and 2009 (n 5 9,441). The SCR records newly diagnosed cases of cancer in Sweden, with an estimated completeness exceeding 97% for solid tumors. 34 For each woman, we included the first recorded primary cancer which was an invasive breast cancer (International Classification of Disease version 7 code 170, pathoanatomical disease code 096). Essentially 100% of the tumors were verified by a clinician and a pathologist. 35 By use of the personal identification number assigned to all residents of Sweden, clinical information was added to the cohort by record linkage to the Swedish Breast Cancer Quality Registers (BCQR) from 1992 to 2009. 36 The BCQR reached national coverage in 1992 (including six regions: the North, Uppsala-€ Orebro, Stockholm-Gotland, South-East, South and West health care regions), with separate reporting from that to the SCR. Of the 9,441 breast cancer cases identified in the SCR, we found information in the BCQR for 9,006 (95%) women using a matching criterion of at most 690 days difference in the recorded diagnosis dates. For the majority of these women (72%), the date of diagnosis was identical in both registers. If more than one tumor was diagnosed on the same date in the BCQR, the largest tumor was included.
We retrieved information on dates of childbirths from the Swedish Multi-Generation Register (MGR), which includes parent-child links for residents born 1932 or later. Record linkage between the MGR and SCR provided information on family history of breast cancer in mothers and sisters of the breast cancer patients. Information on education, migrations and deaths until end of 2012 was obtained from the Swedish Education Register, Cause of Death Register and the Total Population Register.
Exposure
PABC was defined as a malignancy diagnosed during pregnancy (within 9 months prior to delivery date) or 0-24 months after childbirth (split into 0-6, 6-12 and 12-24 months intervals). Women who were nulliparous at diagnosis or diagnosed >2 years after childbirth (split into 2-5, 5-10 and >10 years intervals) were defined as non-PABC. If a woman had more than one delivery within the 10 year window, the delivery closest to the breast cancer diagnosis was used as index pregnancy.
Outcomes
Information from the BCQR included histological type, clinical and pathologic tumor size, nodal status, metastasis (TNM) stage, Elston grade, ER, PR and human epidermal growth factor receptor 2 status (HER2). Subtype was defined according to the St Gallen criteria 37 using ER, PR and HER2, but modified as information on Ki-67 was missing: Luminal A-or B-like HER2 negative (ER1, PR any, HER2-); luminal B-like HER2 positive (ER1, PR any, HER21); HER2 positive nonluminal (ER-, PR-, HER21); triple negative (ER-, PR-, HER2-); and ER-/PR1 (ER-, PR1, HER2 any). Data on certain tumor characteristics were fully missing in some regions and years, reflecting regional protocols. To maximize the use of data, we included different subsets of years and regions in univariable analyses of each tumor characteristic (Supporting Information eTable 1). This pattern of administrative missingness was similar for women with PABC and non-PABC. Even in regions with available data, some women had missing values for other unknown reasons (reported in the tables). Data on clinical TNM was available in four regions (including 5,974 women), pathologic T in five regions (7,652 women) and pathologic TNM in four regions (6,651 women). Information on ER/PR/HER2 status and grade was recorded in all regions but was unavailable for some years (analyses included 8,447 women for ER/PR status, 3,121 for HER2 status and 5,344 for grade).
We retrieved information from the BCQR on surgical treatment for >90% of women. Because of inconsistencies in recorded treatment data, information on adjuvant chemotherapy was only available from five regions, while data on neoadjuvant treatment (predominantly chemotherapy) were only available from three regions. Treatments were recorded as "intention-to-treat," and no information on timing of treatment was available.
To capture short-term and long-term effects, we assessed mortality rates among patients up to 5 and 10 years after diagnosis. Follow-up was defined from date of breast cancer diagnosis until death, emigration, end of study in 2012 or maximum follow-up of 5 (or 10) years since diagnosis, What's new? Women who get breast cancer during or shortly after pregnancy fare worse than those whose cancer doesn't coincide with pregnancy. To help understand why, these authors collected data on a population based cohort, comparing tumor characteristics for childless women, women with pregnancy-associated cancer, and women diagnosed more than 2 years after pregnancy. Pregnancy-associated breast cancers, they discovered, often were more challenging to treat from the moment of discovery. More of them are hormone receptor negative, higher grade, and advanced stage. Thus, the worse outcome appears to be explained by more adverse tumor characteristics at diagnosis. whichever came first. The outcome was death due to any cause, of which the majority (>94%) was attributed to breast cancer. In interaction analyses of time-since-pregnancy and tumor characteristics, only 10 year mortality rates were assessed.
Statistical analysis
We report numbers (N) and proportions (%) of tumor characteristics at diagnosis in different time windows since pregnancy. To account for confounding by age, numbers and proportions were age-standardized, using direct standardization with the age distribution in women diagnosed during pregnancy and up to 12 months postdelivery as the standard. 38 The standardized proportions in each time window were tested versus nulliparous women using Pearson v 2 tests. Mortality rates among the patients were estimated as the number of deaths over person-time at risk in each exposure group. The association between time-since-pregnancy and mortality rates was analyzed using Cox regression estimating hazard ratios (HR) with 95% confidence intervals (CI), and including adjustments for age, year, education and region. Further adjustment for parity or family history did not change the estimates and were not included in the final models. Further, we adjusted for tumor characteristics (pathologic T/N stage and ER/PR status) in a stepwise manner. The proportional hazards assumption was assessed using Schoenfeld residuals, and time-dependent (nonproportional) effects of N stage and ER/PR status were included in the models. To include smooth time-dependent associations we fitted flexible parametric models (FPM) with results shown graphically. 39 Only women with complete information on all covariates in the fully adjusted model were included in all models. The level of significance was 5% and all tests were two sided.
The study was approved by the Ethical Review Board, Stockholm, Sweden.
Results
In total, 778 women were diagnosed with PABC (97 women during pregnancy, 92 during 0-6 months postdelivery, 178 during 6-12 months postdelivery and 411 during 12-24 months postdelivery). Compared to the 1,661 nulliparous women with breast cancer, women with PABC were younger and more often diagnosed in the recent period. There were no differences in educational level, family history status or tumor histology between the two groups ( Table 1) .
We identified 1,277 women diagnosed 2-5 years postdelivery and 2,321 women diagnosed 5-10 years postdelivery. Compared to nulliparous women with breast cancer, women diagnosed 2-5 years postdelivery were younger at diagnosis, while women diagnosed 5-10 years postdelivery were older. There were only minor differences between women diagnosed 2-10 years postdelivery and nulliparous women with regard to period of diagnosis, education, family history and histology.
TNM stage
Following age-standardization, women diagnosed during pregnancy and up to 12 months postdelivery had larger tumors and more often spread to lymph nodes compared to nulliparous women, a pattern which was most pronounced in women diagnosed 0-6 months postdelivery (Table 2) . Women diagnosed with breast cancer within 1 year of delivery had more often distant metastases (stage IV), but numbers were low and the differences nonsignificant. The associations were similar for clinical and pathologic TNM stage. A sensitivity analysis excluding women with a record of neoadjuvant treatment (11% of patients) revealed a similar magnitude of difference in pathologic TNM stage.
Compared to nulliparous women with breast cancer, women diagnosed 2-10 years postdelivery had a similar distribution of tumor size, but nodal involvement was more common ( Table 2) .
ER/PR/HER2 status
Compared to nulliparous women with breast cancer, ER negative tumors were more common in women diagnosed during pregnancy and up to 6 months postdelivery, a finding which was most pronounced in tumors detected 0-6 months postdelivery (Table 2) . A similar pattern was observed for PR negative tumors, but the association remained up to 5 years after delivery. Associations with HER2 status were less consistent, but HER2 positive tumors were more common in women diagnosed 0-6 and 12-24 months postdelivery. A somewhat higher proportion of HER2 positive tumors was also observed in women diagnosed 5-10 years after delivery.
Triple-negative tumors and HER2 positive nonluminal tumors were more common, while luminal tumors were less common, in women diagnosed during pregnancy and up to 1 year postdelivery (Table 2) . Associations with grade were less consistent, but high grade tumors were more common in pregnant women and women diagnosed 6-24 months postdelivery.
Among women with ER/PR positive tumors, there was no difference in pathologic TNM stage for women diagnosed during pregnancy and within 6 months of delivery compared to nulliparous women, but there was a modest shift towards more advanced tumors among women diagnosed 6-12 months postdelivery (Table 3) . Among women with ER/PR negative tumors, a shift toward more advanced tumors was observed during pregnancy and within 6 months of delivery, and less pronounced 6-12 months postdelivery.
Compared to nulliparous women, women with PABC more often had mastectomy than breast conserving surgery, and had higher rates of adjuvant chemotherapy (Supporting Information eTable 2). However, women diagnosed 2-10 years postdelivery also had higher proportions of mastectomy and adjuvant chemotherapy compared to nulliparous women. Neoadjuvant treatment was given to higher extent to women Cancer Epidemiology diagnosed during the first year after delivery compared to nulliparous women.
Survival
Compared to women with non-PABC, women with PABC had a higher mortality rate with a peak in the HR around 2 years after diagnosis following adjustment for age, calendar year, education and region (Fig. 1, left panel) . At around 7 years postdiagnosis, there was no difference in the mortality rates between women with PABC and non-PABC. The HR was reduced and nonsignificant after adjustment for T/N stage and ER/PR status (Fig. 1, right panel) .
Assessing different time windows around pregnancy, the mortality rate was increased in women diagnosed with breast cancer during and within 5 years of pregnancy compared to nulliparous women, with the strongest association observed in women diagnosed during pregnancy and the first year postdelivery (Table 4) . Additional adjustment for pathologic T/N stage and ER/PR status yielded reduced and nonsignificant HRs. Nodal status and ER/PR status had the greatest Parity at diagnosis No., observed number; No.*, age-standardized number; %*, age-standardized proportion; TNM, tumor size, nodal status, metastasis; BC, breast cancer; PABC, pregnancy-associated breast cancer; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor2; Lum, luminal.
mediating effect. The findings were similar for 5 and 10 year mortality rates, though less pronounced in the latter. In a sensitivity analysis restricted to a subset of the data, further adjustments for adjuvant chemotherapy did not change HRs associated with PABC (Supporting Information eTable 3). Interaction analyses revealed that women diagnosed during pregnancy and within 12 months of delivery had an increased HR if they were older, had less advanced disease (node negative, TNM stage 1 (nonsignificant)) or ER positive disease (significant) ( Table 4) . Similar, though weaker, associations were observed among women diagnosed 1-5 years postdelivery.
Discussion
Using a large population-based cohort, we found that women diagnosed with breast cancer during pregnancy or within 1 year after delivery present with more adverse tumor characteristics than nulliparous women, including more advanced tumor stage, ER/PR negativity and high grade. Tumors with the poorest prognostic characteristics were observed during the first 6 months postdelivery, where around 60% of the tumors were ER/PR negative compared to 30% in nulliparous women. The poorer prognosis observed in women with PABC was almost fully explained by adverse tumor characteristics.
Tumors detected during pregnancy and within 2 years postdelivery
Corroborating earlier results, [5] [6] [7] [8] [10] [11] [12] 17, 21 we found more advanced TNM stage tumors in women diagnosed with breast cancer during pregnancy and within 1 year of delivery. This may reflect that characteristics associated with rapid tumor progression, such as ER/PR negativity and HER2 positivity were more common in women with PABC. Similar findings have previously been reported in some, [5] [6] [7] 10, 11, 21 but not all studies. 17 In accordance with the results from the largest study to date on breast cancer during pregnancy, 5 we observed a higher proportion of triple-negative tumors during pregnancy and within 1 year of delivery. We also observed a higher proportion of HER2 positive nonluminal tumors in this time window. In addition, earlier studies have found evidence of a lower risk of breast cancer during pregnancy followed by a small increase in risk postdelivery. 1, 2, 4 This risk pattern may, in light of the present findings, reflect a suppression of hormone receptor positive tumors during pregnancy, rather than an increased risk of hormone receptor negative tumors. Lower incidences of epithelial tumors have been observed among patients with immune deficiency due to AIDS/HIV or organ transplantation. 40 However, it is unknown whether pregnancy-induced immunological changes may lead to a suppression of tumors or act differently on hormone receptor specific tumors. Hormone receptor negative tumors are insensitive to the increased levels of estrogen during pregnancy but may indirectly be stimulated via increased angiogenesis in the tumor microenvironment. 41 Other possible explanations for the TNM stage and subtype distributions of PABC tumors include diagnostic delays of smaller tumors due to masking, tumor growth induced by pregnancy hormones, or a protumorigenic environment during the involution process of the breast tissue. 42 In a stratified analysis, the TNM stage was more advanced closer to pregnancy for ER/PR negative tumors, while ER/PR positive tumors were more advanced further away from delivery. These findings indicate that tumor growth or the masking of pregnancy (diagnostic delay) acts differently on aggressive and less aggressive tumors. The increased mortality rate in women with PABC was almost fully explained by T/N stage and ER/PR status. Similar findings have been reported in two earlier studies 6, 22 but are in contrast to the majority of studies where the association remained after adjustment for tumor characteristics. 3, 7, 17, 18, [25] [26] [27] 43 The largest study to date on pregnant women with breast cancer, found no difference in mortality rates compared to nonpregnant women, neither before nor after adjustment for tumor characteristics. 5 If a poorer prognosis in women with PABC would reflect diagnostic delays only, no difference in survival would be expected when comparing PABC and non-PABC women with similar TNM stage at diagnosis, assuming the same underlying subtype. However, because of the differential tumor growth by subtype 44 and the possible differential masking effect of pregnancy, a poorer prognosis may still be observed even after adjustment for TNM stage. Hence, adjustment for both TNM stage and hormone receptor status is important. Furthermore, since the effect of PABC on survival was essentially fully explained by tumor characteristics, additional adjustment for treatment did not change the results. The lower survival among PABC women with less aggressive tumors (node negative, ER/PR positive) warrants further research. Elevated mortality rates in women with ER positive PABC tumors has been reported in two previous studies. 18, 21 While survival is high in this patient group, our finding may reflect a direct adverse effect of pregnancy.
Similar to previous results, 22, 24 we found the strongest effects on survival during the first 5 years after diagnosis. Hence, the influence of pregnancy on prognosis appears to be restricted to the time period shortly after diagnosis.
Tumors detected 2-10 years postdelivery
Our finding of a higher proportion of nodal involvement in women diagnosed 2-10 years postdelivery has previously been reported in some, 13, 26, 27, 33 but not in all studies. 8, 14 Tumors diagnosed many years after delivery are unlikely to have been affected by pregnancy-related diagnostic delays.
Although we found higher rates of PR negative tumors in women diagnosed up to 5 years postdelivery, several studies have found no evidence of increased rates of ER or PR negative tumors or high-grade tumors diagnosed 2-10 years postdelivery. 9, 13, 18, 20, 26, 27, 30 In line with several, 24, 25, 27, 28, 32 but not all, 14,22,26 studies we found evidence of an increased mortality rate in women diagnosed 2-5 years postdelivery before adjustment for tumor characteristics. After adjustment for tumor characteristics, the hazard ratios were attenuated and nonsignificant corroborating some of these studies. 14, 22, 27, 28 Our finding is unlikely to be an effect of lower treatment intensity or lower screening attendance. This is one of the largest studies to date evaluating breast cancer characteristics and prognosis in relation to time-sincepregnancy. The population-based setting, with extensive clinical data, detailed information on pregnancies and a virtually complete follow-up, allowed investigation of subgroups. 
Cancer Epidemiology
Many previous studies have been based on single-institution or combined hospital-based materials, 5, 6, 10, 11, 13, [17] [18] [19] 30 while others have utilized cancer registry data. 3, 7, 8, 12, 27, 31, 33 Further strengths include the list of covariates controlled for in the analysis, by standardization, stepwise modelling and inclusion of time-dependent effects, where the higher mortality rates in node positive and ER/PR negative groups was given special attention.
Despite the large dataset at hand, missing data on important characteristics, such as HER2 and grade, hampered the analysis. However, since the majority of missing data was administrative (random), and similar for women with PABC and non-PABC, the analytical sample should not be biased. Data on systemic treatment were incomplete and partly missing. However, the available data suggest that women with PABC had similar or more intensive treatment compared to nulliparous women. Women diagnosed after delivery are likely to have been treated according to national guidelines, and similarly to women with non-PABC, given the same tumor characteristics. Other limitations included potential misclassification of tumor features due to changes in measurements over time, but this is likely to have affected PABC and non-PABC women nondifferentially. Since no information on terminated pregnancies was available, an unknown number of breast cancer detected in terminated pregnancies were misclassified as non-PABC. Also, we had no information on breastfeeding or whether tumors were detected by invitational screening mammography. During the study period about half of Sweden's counties invited women to screening from 40 years. 45 Our results provide further support that women with PABC present with more adverse tumor characteristics, findings which largely explain the poorer prognosis observed in this patient group. We conclude that, women with PABC have as good survival as any woman with breast cancer with similar tumor characteristics in their age group.
